Literature DB >> 2897902

The potential for added benefits with beta-blockers and calcium antagonists in treating cardiovascular disorders.

W G Nayler1.   

Abstract

Whereas the beta-blockers were heralded as the drugs of the sixties and early seventies, the calcium antagonists have established themselves as the drugs of the eighties. However, despite the widely differing pharmacology of these 2 classes of drugs, they are often used for the management of the same cardiovascular disorders, including angina pectoris, ischaemic heart disease and hypertension. Whether some advantage might be gained from their combined use depends upon a precise understanding of how these drugs interact with the cardiovascular system. It also requires a clear recognition of the different pharmacological profiles displayed by individual members of the same class of drugs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897902     DOI: 10.2165/00003495-198800354-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  23 in total

Review 1.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

2.  Effect of verapamil on contractility, oxygen utilization, and calcium exchangeability in mammalian heart muscle.

Authors:  W G Nayler; J Szeto
Journal:  Cardiovasc Res       Date:  1972-03       Impact factor: 10.787

Review 3.  Antihypertensive treatment and serum lipoproteins.

Authors:  P Weidmann; D E Uehlinger; A Gerber
Journal:  J Hypertens       Date:  1985-08       Impact factor: 4.844

Review 4.  Calcium antagonists: a new class of drugs.

Authors:  W G Nayler; J D Horowitz
Journal:  Pharmacol Ther       Date:  1983       Impact factor: 12.310

5.  [3H]-verapamil binding to rat cardiac sarcolemmal membrane fragments; an effect of ischaemia.

Authors:  J S Dillon; W G Nayler
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

6.  The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation.

Authors:  J Nilsson; M Sjölund; L Palmberg; A M Von Euler; B Jonzon; J Thyberg
Journal:  Atherosclerosis       Date:  1985-12       Impact factor: 5.162

7.  Verapamil in acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction.

Authors: 
Journal:  Eur Heart J       Date:  1984-07       Impact factor: 29.983

8.  Regional contractility. Selective depression of ischemic myocardium by verapamil.

Authors:  H J Smith; R A Goldstein; J M Griffith; K M Kent; S E Epstein
Journal:  Circulation       Date:  1976-10       Impact factor: 29.690

9.  Release of endogenous catecholamines in the ischemic myocardium of the rat. Part A: Locally mediated release.

Authors:  A Schömig; A M Dart; R Dietz; E Mayer; W Kübler
Journal:  Circ Res       Date:  1984-11       Impact factor: 17.367

10.  Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1986-07-12       Impact factor: 79.321

View more
  1 in total

Review 1.  Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection.

Authors:  Bernard Waeber; François Feihl; Luis M Ruilope
Journal:  Drugs       Date:  2009       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.